A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel
[article]
2022
medRxiv
pre-print
Importance: While comprehensive tumor molecular profile by whole exome and RNA sequencing (WES/RNA-Seq) is now feasible in routine practice, it remains unclear whether this increases therapeutic options as compared to a more limited targeted gene panel (TGP) plus array-based comparative genomic hybridization (aCGH) in advanced cancer patients. Objective: To determine the added value of WES/RNA-Seq in advanced and refractory cancer patients who had no molecular-based treatment recommendation
doi:10.1101/2022.02.08.22270301
fatcat:dvzg4yuyqrd55ilplsb6ee37km